4-[(3S)-piperidin-3-ylmethoxy]-6-(propan-2-yloxy)quinoline-7-carboxamide | 1817626-56-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-[(3S)-piperidin-3-ylmethoxy]-6-(propan-2-yloxy)quinoline-7-carboxamide
• 英文别名: US10329302, Example 2；4-[[(3S)-piperidin-3-yl]methoxy]-6-propan-2-yloxyquinoline-7-carboxamide
• CAS: 1817626-56-4
• 化学式: C₁₉H₂₅N₃O₃
• 分子量: 343.426
• InChiKey: LGWAIKZDEAAWBY-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  86.5
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Bicyclic-Fused Heteroaryl or Aryl Compounds
  申请人：Pfizer Inc.

  公开号：US20150284405A1

  公开（公告）日：2015-10-08

  Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物的异构体和药学上可接受的盐已被披露，其中所述化合物具有如规范中定义的Ia式结构。相应的药物组合物、治疗方法、合成方法和中间体也已被披露。
• BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS
  申请人：Pfizer Inc.

  公开号：EP3536685A1

  公开（公告）日：2019-09-11

  Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment of autoimmune and inflammatory diseases associated with Interleukin-1 Receptor Associated Kinase (IRAK), methods of synthesis, and intermediates are also disclosed.

  本发明公开了化合物、同系物和药学上可接受的盐，其中化合物具有式 Ia 的结构、 的结构。还公开了相应的药物组合物、与白细胞介素-1受体相关激酶（IRAK）相关的自身免疫性和炎症性疾病的治疗方法、合成方法和中间体。
• Bicyclic-fused heteroaryl or aryl compounds
  申请人：Pfizer Inc.

  公开号：US10329302B2

  公开（公告）日：2019-06-25

  Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明公开了化合物、化合物的同系物和药学上可接受的盐，其中化合物具有说明书中定义的式 Ia 结构。 还公开了相应的药物组合物、治疗方法、合成方法和中间体。
• Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
  申请人：Acerta Pharma B.V.

  公开号：US20200069668A1

  公开（公告）日：2020-03-05

  Therapeutic combinations of an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of an IRAK4 inhibitor and a BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.
• US9458168B2
  申请人：——

  公开号：US9458168B2

  公开（公告）日：2016-10-04